Table 2.
Association between SENP1 immunostaining results and prostate cancer phenotype in all cancers
| Parameter | SENP1 | p value | ||||
|---|---|---|---|---|---|---|
| n evaluable | Negative (%) | Weak (%) | Moderate (%) | Strong (%) | ||
| All cancers | 9,516 | 65.5 | 12.3 | 14.9 | 7.3 | |
| Tumor stage | <0.0001 | |||||
| pT2 | 6,143 | 68.2 | 11.1 | 14.1 | 6.6 | |
| pT3a | 2,137 | 61.8 | 13.7 | 15.9 | 8.7 | |
| pT3b-4 | 1,203 | 58.1 | 15.8 | 17.6 | 8.5 | |
| Gleason grade | <0.0001 | |||||
| ≤3 + 3 | 2,135 | 72.5 | 9.2 | 11.6 | 6.7 | |
| 3 + 4 | 5,451 | 65.3 | 11.7 | 15.5 | 7.5 | |
| 4 + 3 | 1,445 | 58.4 | 16.2 | 17.6 | 7.8 | |
| ≥4 + 4 | 442 | 58.1 | 20.8 | 14.9 | 6.1 | |
| Lymph node metastasis | 0.0019 | |||||
| N0 | 5,472 | 62.3 | 12.6 | 16.6 | 8.5 | |
| N+ | 526 | 56.8 | 18.4 | 17.5 | 7.2 | |
| Preop. PSA level (ng/ml) | 0.0037 | |||||
| <4 | 1160 | 64.2 | 12.2 | 15.9 | 7.6 | |
| 4-10 | 5702 | 66.8 | 11.2 | 15.0 | 7.0 | |
| 10-20 | 1892 | 63.4 | 14.6 | 14.5 | 7.5 | |
| >20 | 666 | 62.3 | 14.9 | 14.3 | 8.6 | |
| Surgical margin | 0.3216 | |||||
| negative | 7,549 | 65.9 | 12.1 | 14.9 | 7.1 | |
| positive | 1,797 | 63.8 | 13.0 | 15.2 | 8.0 | |